2395.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...

Stats
Šios dienos apimtis	196 700
Vidutinė apimtis	307 805
Rinkos kapitalizacija	63.91B
EPS	¥0 ( 2024-02-01 )
Kita pelno data	( ¥12.99 ) 2024-05-08
Last Dividend	¥30.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	11.62
ATR14	¥0.932 (0.06%)

Tūris Koreliacija

Ilgas: 0.15 (neutral)

Trumpas: -0.99 (very strong negative)

Signal:(61.875) Neutral

Shin Nippon Biomedical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Shin Nippon Biomedical Koreliacija - Valiuta/Žaliavos

-0.62
( weak negative )

-0.44
( neutral )

-0.14
( neutral )

-0.46
( neutral )

0.74
( moderate )

0.44
( neutral )

Shin Nippon Biomedical Finansinės ataskaitos

Annual	2022
Pajamos:	¥25.09B
Bruto pelnas:	¥13.05B (52.00 %)
EPS:	¥145.57

FY	2022
Pajamos:	¥25.09B
Bruto pelnas:	¥13.05B (52.00 %)
EPS:	¥145.57

FY	2022
Pajamos:	¥17.75B
Bruto pelnas:	¥9.69B (54.58 %)
EPS:	¥171.20

FY	2021
Pajamos:	¥15.11B
Bruto pelnas:	¥7.55B (49.99 %)
EPS:	¥87.95

Financial Reports:

No articles found.

Shin Nippon Biomedical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥30.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Shin Nippon Biomedical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.81 - Stable (3.83%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥0.500	2004-03-26
Last Dividend	¥30.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	¥99.00	--
Avg. Dividend % Per Year	0.00%	--
Score	2.65	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.81
Div. Directional Score	7.68	--

Next Divdend (Est)
(2024-07-08)

¥0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6879.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6250.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
4970.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4182.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3361.T	Ex Dividend Junior	2024-04-26	Annually	0.00%
2438.T	Ex Dividend Junior	2024-04-26	Annually	0.00%
9948.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
8957.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
8060.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
7326.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.0771	1.200	7.43	8.92	[0 - 0.3]
returnOnEquityTTM	0.192	1.500	8.98	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.496	0.800	7.52	6.02	[1 - 3]
quickRatioTTM	0.835	0.800	9.80	7.84	[0.8 - 2.5]
cashRatioTTM	0.571	1.500	7.94	10.00	[0.2 - 2]
debtRatioTTM	0.374	-1.500	3.77	-5.65	[0 - 0.6]
interestCoverageTTM	30.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.884	-1.500	6.46	-9.69	[0 - 2.5]
grossProfitMarginTTM	0.522	1.000	4.63	4.63	[0.2 - 0.8]
operatingProfitMarginTTM	0.150	1.000	9.01	9.01	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.134	1.000	-0.368	-0.368	[0.2 - 2]
assetTurnoverTTM	0.374	0.800	-0.839	-0.671	[0.5 - 2]
Total Score				10.55

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.63	1.000	8.93	0	[1 - 100]
returnOnEquityTTM	0.192	2.50	9.34	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.25	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	85.79	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.776	1.500	-8.51	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.134	1.000	9.16	0	[0.1 - 0.5]
Total Score				4.81

Shin Nippon Biomedical

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.